November 2014 - The Reporter
December 13, 2021
Co-enrolled biomedical engineering courses for med students expand
New courses in Precision Medicine and Entrepreneurship in Medicine from leading BME faculty will debut in spring 2022 semester.
Published in
Programs & Curricula
December 09, 2021
Achieve mental clarity through mindfulness meditation this spring
Join University Recreation’s spring mindfulness series Jan. 25-April 14 to begin practicing mindfulness strategies to reduce stress and improve mental health.
Published in
Be Healthy
December 06, 2021
Using AI to translate old code and fix aging computer systems
UAB computer scientists are contributing to a DARPA-funded initiative with artificial intelligence-based programming languages that allow humans to understand the “safety and correctness of code in the wild.”
Published in
Grants Awarded
December 02, 2021
3 chosen as UAB VIPs
Amy Allon, Corey Agricola and Jessica Gunnin are the three honorees of the UAB Shared Values in Action Program for this quarter.
Published in
Awards & Honors
November 30, 2021
Spreading hope, support for grad students during Stress Less Week
Graduate students and postdocs in the Advanced Mental Health Promotion course will raise awareness and share encouragement — including custom stickers — in a series of events this week.
Published in
Programs & Curricula
November 29, 2021
Building the right credentials for today's hybrid workforce
New graduate certificates in academic advising and diversity, equity, inclusion and advocacy are the latest in a series of practitioner-oriented programs at UAB. Find out why students and faculty are excited, and how the AL ASSET initiative offers opportunities statewide.
Published in
Programs & Curricula
November 29, 2021
As simulation efforts expand at UAB, a new structure focuses on growth
One of the largest simulation groups in the country will become two separate teams as of July 2022 to meet current and future growth: UAB Clinical Simulation for the Health System and the Office of Interprofessional Simulation for the academic campus.
Published in
Campus News
You may be eligible to participate in a research study about the effects of sacubitril/valsartan on how your body handles insulin and glucose. This medication is related to the heart. Eligible participants must be healthy men and women, African American, and have no history of diabetes, heart problems, or kidney problems. The study involves performing some exercise, taking sacubitril/valsartan, and collecting blood samples. Participants will be compensated. To participate, please contact Nehal at 205-934-7173 or email us at nauticalstudy@uabmc.edu.
Published in
Clinical Trials
November 23, 2021
Healthy volunteers are needed for the Exercise and Beta-Blocker Study
You may be eligible to participate in a research study about the effects of Exercise and Metoprolol (a blood pressure pill) on a protein in your blood. This protein is related to heart disease. Eligible participants must be Healthy men and women, African American or Caucasians, and have no history of diabetes, heart problems, or kidney problems. The study involves performing the exercise, taking metoprolol, consuming prepared meals, and collecting blood samples. Participants will be compensated. Please e-mail Nehal Vekariya at exercisebetastudy@uabmc.edu or call us at 205-934-7173 if you are interested.
Published in
Clinical Trials
November 23, 2021
Non-invasive radiation treatment for ventricular tachycardia
Clinical trial evaluating a novel, non-invasive radiation treatment for ventricular tachycardia refractory to medication and catheter ablation The UAB Departments of Radiation Oncology and Cardiology are looking for patients with ventricular tachycardia (VT) not controlled by medications and catheter ablation. The trial will allow patients suffering from VT despite standard of care regimens to undergo non-invasive cardiac radioablation (CRA; a type of stereotactic body radiotherapy) to the area of the heart responsible for their symptoms. Stereotactic body radiotherapy is delivered with a device called the linear accelerator, which is primarily used to treat patients with cancer. UAB is one of the first centers in the U.S. to obtain a Food and Drug Administration (FDA) investigational device exemption for use of the linear accelerator in this capacity on a phase I/II trial. The study is being conducted in collaboration with the Washington University School of Medicine in St. Louis, a center which pioneered this promising technique in the U.S. For more information on the RAD 1901 trial, please contact Adelyn Gillon, clinical research coordinator, at 205.975.3019 or agillon@uabmc.edu" contenteditable="false">agillon@uabmc.edu.
Published in
Clinical Trials
